A SYNTHESIS OF 166,178-IMINOANDROSTANES Gary J. Matthews and Alfred Hassner

Department of Chemistry, University of Colorado, Boulder, Colorado 80302 (Received in USA 18 February 1969; received in UK for publication 13 April 1969)

The variable conformational and steric influences in the steroid nucleus necessitate a variation in the choice of reagents used for the synthesis of fused steroidal aziridines. Although iodine isocyanate readily reacts with Δ^2 -steroids¹ it is inapplicable to most other steroid olefins and leads to very low yields of 16 β , 17 β -iminoandrostan-3 β -ol from the corresponding 16-androstene. We wish to report a convenient method to fuse the interesting aziridine ring system² to the biologically important β -face of the steroidal D-ring.³

Iodine azide⁴ attacks 3- β -acetoxy-16-androstene (1) from the α -side and reqiospecifically⁵ to give 90% yield 3B-acetoxy-16B-azido-17 α -iodoandrostane (2) [mp 157-158°; ir 2100, 1740, 1250, and 1030 cm⁻¹; nmr τ 5.33 (m broad, 2, W_{2} =18 Hz), 5.10 (d, 1, J=1.5Hz, $17\alpha-H$), 7.99 (s, 3, CH_3CO_2 -), 9.02 (s, 3, H-18), and 9.18 (s, 3, H-19)].⁶ Exposure of 2 to an excess of LAH in ether afforded analytically pure 16β , 17β -iminoandrostan- 3β -ol (3) in 62% yield (mp shows the crystalline forms to transpose at ca. 75° before melting at 154-155°) . A two step synthesis via the diborane reduction of 2 to the iodo amine 4 gives3 but in lower yield. The presence of the aziridine ring is easily proved by acetylation with acetic anhydride and pyridine to 5 (mp 153-153.5°; ir 1730, <u>1695</u>, 1395, 1375, 1285, 1250 and 1026 cm⁻¹; nmr τ5.38 (s broad, 1, W½20Hz, 3α-<u>H</u>), 6.98 (t,1,J=<u>ca</u>. 5Hz, 16α-<u>H</u>), 7.23 (d, 1, J=5Hz, $17\alpha-\underline{H}$), 7.95 (s, $C\underline{H}_3CON$), 8.01 (s,3, $C\underline{H}_3CO_2$), and (s,6, H-18 and H-19). The single amide band at 1695 cm^{-1} quickly identifies a tertiary amide and the triplet-doublet pattern for the 16 and 17 proton is identical to the pattern of the 16 β ,17 β -epoxide.⁷ These spectra are characteristically different from those of the iodo amide 6 which confirm the 17lpha-location of the iodo group

1833


No.23

by the retention of a doublet for the 17-proton (mp 156-157°; ir 3300, 3070w, 1730, <u>1645</u>, <u>1545</u>, 1240, 1150, 1083, 1020, 958, and 901 cm⁻¹; nmr $\tau 2.05$ (d broad, 1, N<u>H</u>), 5.30 (m,2, $W_{2}^{1}=25Hz$), 5.98 (d, 1, J=2Hz. 17a-<u>H</u>), 7.99 (s,3, C<u>H₃CO₂⁻</u>), 8.03 (s,3, C<u>H₃CON</u>), 9.03 (s,3,H-18), and 9.18 (s,3,H-19).

The unquestionable structure proof of the 16β , 17β -aziridine stereochemistry was assured by the independent stereorational synthesis [1+7+8+9+5] in which the nitrogen function was introduced on the β -side by the <u>trans</u>-opening of the α -epoxide 7.


Selective addition (even in the presence of 2 equiv. of iodine azide) to the 16-double bond of $\Delta^{4,16}$ -andorstadien-3-one (10) is possible and some selective addition to the 16-double bond of $\Delta^{5,16}$ -dienes were observed. 16β-Azido-17α-iodo- Δ^4 -androsten-3-one (11) was converted by LAH to the 3-hydroxy-16β,17β-aziridines. The major isomer was easily purified by crystallization in the form of the N,0-diacetyl derivative 12 (mp 145-147°, ir 1725, 1690, 1650 sh, 1370, 1265, 1255 and 1018 cm⁻¹; nmr $\tau 6.74$ (s, $W_2=3Hz$, 4-H, protruding out of a multiplet, $W_2=18Hz$), 6.93 (t broad, 1, J=4.5Hz, $16\alpha-H$), 7.21 (d,1,J=5Hz), 17a-H), 7.92 (s,3, CH_3CON), 7.98 (s,3, $CH_3CO_2^{-1}$), 8.96 (H-19), and 9.16 (H-18).

It should be added that the recent development of a high yield regioselective synthesis of 16-androstenes⁸ greatly enhances the potential of this synthetic method. Thus we were able to obtain the 16-olefins 1 and 10 by treatment of 17-tosylhydrazones with methyl lithium in glyme without any interferring rearrangement of the neopentyl system.



Acknowledgment: This investigation was supported by the U.S. Public Health Service Grant CA-04474 from the National Cancer Institute.

1834



REFERENCES

1. A. Hassner and C.H. Heathcock, J. Org. Chem., 30, 1748 (1965).

2. J.A. Montgomery, Cancer Research, 19, 447 (1959).

3. M.E. Wolff, W.Ho, and R. Kwok, J. Med. Chem, 7, 577 (1964).

4. F.W. Fowler, A. Hassner, and L.A. Levy, <u>J. Amer. Chem. Soc</u>., 89, 2077 (1967).

5. A. Hassner, <u>J. Org. Chem.</u>, 33, 2684 (1968).

6. Satisfactory analyses were obtained for all fully characterized compounds; ir spectra were taken in KBr.

7. K. Tori, T. Komeno, and T. Nakagawa, <u>J. Org. Chem</u>., 29, 1136 (1964).

8. R.H. Shapiro and M.J. Heath, J. Amer. Chem. Soc., 89, 5734 (1967).